C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 5/07 (2010.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) A61P 37/04 (2006.01) C12N 5/10 (2006.01) C12N 15/09 (2006.01) C12N 15/85 (2006.01)
Patent
CA 2698079
T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.
Degraw Juli
Heiskala Marja
Jackson Michael R.
Leturcq Didier J.
Moriarty Ann
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Ortho-Mcneil Pharmaceutical Inc.
LandOfFree
A cell therapy method for the treatment of tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with A cell therapy method for the treatment of tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A cell therapy method for the treatment of tumors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1397514